Articles

The US District Court for the District of Arizona entered into consent decree against Smart Women’s Choice and its CEO to stop the company from distributing unapproved contraceptive drugs.

Consent Decree Entered Against Arizona Company

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

Andy Geall, co-founder and chief development officer at Replicate Bioscience continues the discussion on the development history of mRNA therapeutics.

Discussing the Origins of the mRNA Therapeutics Field (Part Two)

Under the agreement, the companies will discover and develop drug candidates targeting two ion channels linked to neurological disorders.

Autifony Signs $770.5 Million License and Collaboration with Jazz Pharmaceuticals

Twist Bioscience now offers its Express Genes rapid gene synthesis service at its Wilsonville, Ore., manufacturing facility.

Twist Bioscience Launches Gene Synthesis Service

Feliza Mirasol is the science editor for 

Lonza’s new GS Effex cell line can help overcome the challenges of developing therapeutic antibodies with increased potency.

Lonza Launches New Cell Line for Higher Potency Antibody Development

The 3M Harvest RC Chromatographic Clarifier, BT500 is the latest addition to the company’s chromatographic clarifier portfolio.

3M Health Care Launches New Chromatographic Clarifier

Novartis and Legend Biotech seek to advance certain CAR-T cell therapy candidates targeting Delta-like ligand protein 3.

Novartis and Legend Biotech Sign Exclusive License Agreement for CAR-T Therapies

Adzynma provides a replacement for low levels of the ADAMTS13 enzyme in patients with congenital thrombotic thrombocytopenic purpura.

FDA Approves First Recombinant Treatment for Rare Blood Clotting Disorder

A discussion with Thomas Langenickel, MD, chief medical officer at Ethris, shines a light on how advances made with mRNA technology are also advancing the industry’s ability to focus on treatment of rare diseases, such as rare lung diseases.

mRNA Advances Allow Drug Development Focus on Rare Diseases (Part One)

Aitia will access Charles River’s Logica drug solution platform to develop therapeutic programs for neurodegenerative disease and oncology.

News